Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Research Report 2023
Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that need to manage long term.
IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.
In this report, we study the drugs for diarrhea predominant irritable bowel syndrome (IBS-D).
Highlights
The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
North America is the largest consumption place of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, followed by Europe. The two account for more than 80% of the consumer market in together. The most used IBS-D drug is XIFAXAN, accounting for more than 60% of the market share, followed by Viberzi and Lotronex. IBS-D drugs are widely sold through hospital pharmacies and retail pharmacies.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.
The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2018-2023. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Global markets are presented by Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs type, along with growth forecasts through 2029. Estimates on sales and revenue are based on the price in the supply chain at which the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs segment by Type
This report has provided the market size (sales and revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market.
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs segment by Sales Channel
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2023 and forecast revenue for 2029.
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by sales channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Frequently Asked Questions
IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.
In this report, we study the drugs for diarrhea predominant irritable bowel syndrome (IBS-D).
Highlights
The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
North America is the largest consumption place of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, followed by Europe. The two account for more than 80% of the consumer market in together. The most used IBS-D drug is XIFAXAN, accounting for more than 60% of the market share, followed by Viberzi and Lotronex. IBS-D drugs are widely sold through hospital pharmacies and retail pharmacies.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.
The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2018-2023. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Bausch Health
- Allergan
- Sebela Pharmaceuticals
- Astellas Pharmaceuticals
- Amneal Pharms
- Pharscin Pharma
Global markets are presented by Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs type, along with growth forecasts through 2029. Estimates on sales and revenue are based on the price in the supply chain at which the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs segment by Type
- XIFAXAN
- Viberzi
- Lotronex
- Other
This report has provided the market size (sales and revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market.
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs segment by Sales Channel
- Hospitals Pharmacy
- Retail Pharmacy
- Other
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2023 and forecast revenue for 2029.
- North America
- United States
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by sales channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Frequently Asked Questions
- Which product segment grabbed the largest share in the Product Name market?
- How is the competitive scenario of the Product Name market?
- Which are the key factors aiding the Product Name market growth?
- Which are the prominent players in the Product Name market?
- Which region holds the maximum share in the Product Name market?
- What will be the CAGR of the Product Name market during the forecast period?
- Which application segment emerged as the leading segment in the Product Name market?
- What key trends are likely to emerge in the Product Name market in the coming years?
- What will be the Product Name market size by 2028?
- Which company held the largest share in the Product Name market?
LIST OF TABLES
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Sales Channel (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2018 Versus 2022)
Table 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) of Manufacturers (2018-2023)
Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2018-2023)
Table 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue of Manufacturers (2018-2023)
Table 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2018-2023)
Table 10. Global Market Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (USD/Unit) of Manufacturers (2018-2023)
Table 11. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Ranking, 2021 VS 2022 VS 2023
Table 12. Global Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Product Type & Application
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 16. Bausch Health Company Information
Table 17. Bausch Health Business Overview
Table 18. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 19. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
Table 20. Bausch Health Recent Developments
Table 21. Allergan Company Information
Table 22. Allergan Business Overview
Table 23. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 24. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
Table 25. Allergan Recent Developments
Table 26. Sebela Pharmaceuticals Company Information
Table 27. Sebela Pharmaceuticals Business Overview
Table 28. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 29. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
Table 30. Sebela Pharmaceuticals Recent Developments
Table 31. Astellas Pharmaceuticals Company Information
Table 32. Astellas Pharmaceuticals Business Overview
Table 33. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 34. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
Table 35. Astellas Pharmaceuticals Recent Developments
Table 36. Amneal Pharms Company Information
Table 37. Amneal Pharms Business Overview
Table 38. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 39. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
Table 40. Amneal Pharms Recent Developments
Table 41. Pharscin Pharma Company Information
Table 42. Pharscin Pharma Business Overview
Table 43. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 44. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
Table 45. Pharscin Pharma Recent Developments
Table 46. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 47. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2018-2023) & (K Units)
Table 48. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2018-2023)
Table 49. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2024-2029) & (K Units)
Table 50. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2024-2029)
Table 51. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 52. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2018-2023)
Table 53. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 54. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2024-2029)
Table 55. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2018-2023) & (K Units)
Table 57. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2024-2029) & (K Units)
Table 58. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 59. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 60. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 61. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2018-2023) & (K Units)
Table 62. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2024-2029) & (K Units)
Table 63. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 64. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 65. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 66. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2018-2023) & (K Units)
Table 67. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2024-2029) & (K Units)
Table 68. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 69. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 70. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2018-2023) & (K Units)
Table 72. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2024-2029) & (K Units)
Table 73. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 74. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 75. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 76. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2018-2023) & (K Units)
Table 77. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2024-2029) & (K Units)
Table 78. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 79. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 80. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2018-2023) & (K Units)
Table 81. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2024-2029) & (K Units)
Table 82. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2018-2023)
Table 83. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2024-2029)
Table 84. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 85. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 86. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2018-2023)
Table 87. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2024-2029)
Table 88. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2018-2023) & (USD/Unit)
Table 89. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2024-2029) & (USD/Unit)
Table 90. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2018-2023) & (K Units)
Table 91. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2024-2029) & (K Units)
Table 92. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2018-2023)
Table 93. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2024-2029)
Table 94. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2018-2023) & (US$ Million)
Table 95. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2024-2029) & (US$ Million)
Table 96. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2018-2023)
Table 97. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2024-2029)
Table 98. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (2018-2023) & (USD/Unit)
Table 99. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (2024-2029) & (USD/Unit)
Table 100. Key Raw Materials
Table 101. Raw Materials Key Suppliers
Table 102. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
Table 103. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers List
Table 104. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends
Table 105. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Drivers
Table 106. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Restraints
Table 107. Authors 12. List of This Report
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Sales Channel (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2018 Versus 2022)
Table 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) of Manufacturers (2018-2023)
Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2018-2023)
Table 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue of Manufacturers (2018-2023)
Table 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2018-2023)
Table 10. Global Market Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (USD/Unit) of Manufacturers (2018-2023)
Table 11. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Ranking, 2021 VS 2022 VS 2023
Table 12. Global Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Product Type & Application
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 16. Bausch Health Company Information
Table 17. Bausch Health Business Overview
Table 18. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 19. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
Table 20. Bausch Health Recent Developments
Table 21. Allergan Company Information
Table 22. Allergan Business Overview
Table 23. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 24. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
Table 25. Allergan Recent Developments
Table 26. Sebela Pharmaceuticals Company Information
Table 27. Sebela Pharmaceuticals Business Overview
Table 28. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 29. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
Table 30. Sebela Pharmaceuticals Recent Developments
Table 31. Astellas Pharmaceuticals Company Information
Table 32. Astellas Pharmaceuticals Business Overview
Table 33. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 34. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
Table 35. Astellas Pharmaceuticals Recent Developments
Table 36. Amneal Pharms Company Information
Table 37. Amneal Pharms Business Overview
Table 38. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 39. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
Table 40. Amneal Pharms Recent Developments
Table 41. Pharscin Pharma Company Information
Table 42. Pharscin Pharma Business Overview
Table 43. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 44. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
Table 45. Pharscin Pharma Recent Developments
Table 46. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 47. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2018-2023) & (K Units)
Table 48. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2018-2023)
Table 49. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2024-2029) & (K Units)
Table 50. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2024-2029)
Table 51. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 52. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2018-2023)
Table 53. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 54. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2024-2029)
Table 55. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2018-2023) & (K Units)
Table 57. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2024-2029) & (K Units)
Table 58. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 59. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 60. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 61. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2018-2023) & (K Units)
Table 62. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2024-2029) & (K Units)
Table 63. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 64. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 65. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 66. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2018-2023) & (K Units)
Table 67. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2024-2029) & (K Units)
Table 68. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 69. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 70. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2018-2023) & (K Units)
Table 72. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2024-2029) & (K Units)
Table 73. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 74. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 75. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 76. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2018-2023) & (K Units)
Table 77. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2024-2029) & (K Units)
Table 78. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 79. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 80. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2018-2023) & (K Units)
Table 81. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2024-2029) & (K Units)
Table 82. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2018-2023)
Table 83. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2024-2029)
Table 84. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 85. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 86. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2018-2023)
Table 87. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2024-2029)
Table 88. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2018-2023) & (USD/Unit)
Table 89. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2024-2029) & (USD/Unit)
Table 90. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2018-2023) & (K Units)
Table 91. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2024-2029) & (K Units)
Table 92. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2018-2023)
Table 93. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2024-2029)
Table 94. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2018-2023) & (US$ Million)
Table 95. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2024-2029) & (US$ Million)
Table 96. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2018-2023)
Table 97. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2024-2029)
Table 98. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (2018-2023) & (USD/Unit)
Table 99. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (2024-2029) & (USD/Unit)
Table 100. Key Raw Materials
Table 101. Raw Materials Key Suppliers
Table 102. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
Table 103. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers List
Table 104. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends
Table 105. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Drivers
Table 106. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Restraints
Table 107. Authors 12. List of This Report
LIST OF FIGURES
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Irritable Bowel Syndrome with Diarrhea (IBS-D) DrugsProduct Picture
Figure 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million), 2018 VS 2022 VS 2029
Figure 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size (2018-2029) & (US$ Million)
Figure 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (2018-2029) & (K Units)
Figure 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (USD/Unit) & (2018-2029)
Figure 9. XIFAXAN Product Picture
Figure 10. Viberzi Product Picture
Figure 11. Lotronex Product Picture
Figure 12. Other Product Picture
Figure 13. Hospitals Pharmacy Product Picture
Figure 14. Retail Pharmacy Product Picture
Figure 15. Other Product Picture
Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers in 2022
Figure 17. Global Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Manufacturing Sites & Headquarters
Figure 18. Global Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Date of Enter into This Industry
Figure 19. Global Top 5 and 10 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players Market Share by Revenue in 2022
Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region in 2022
Figure 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region in 2022
Figure 24. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country in 2022
Figure 25. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2018-2029)
Figure 26. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2018-2029)
Figure 27. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country in 2022
Figure 30. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2018-2029)
Figure 31. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2018-2029)
Figure 32. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country in 2022
Figure 38. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2018-2029)
Figure 39. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2018-2029)
Figure 40. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. China Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country in 2022
Figure 50. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2018-2029)
Figure 51. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2018-2029)
Figure 52. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country in 2022
Figure 56. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2018-2029)
Figure 57. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2018-2029)
Figure 58. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 59. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 60. UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 61. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2018-2029)
Figure 62. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2018-2029)
Figure 63. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Type (2018-2029)
Figure 64. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2018-2029)
Figure 65. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2018-2029)
Figure 66. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Sales Channel (2018-2029)
Figure 67. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain
Figure 68. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Mode & Process
Figure 69. Direct Comparison with Distribution Share
Figure 70. Distributors Profiles
Figure 71. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Opportunities and Challenges
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Irritable Bowel Syndrome with Diarrhea (IBS-D) DrugsProduct Picture
Figure 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million), 2018 VS 2022 VS 2029
Figure 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size (2018-2029) & (US$ Million)
Figure 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (2018-2029) & (K Units)
Figure 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (USD/Unit) & (2018-2029)
Figure 9. XIFAXAN Product Picture
Figure 10. Viberzi Product Picture
Figure 11. Lotronex Product Picture
Figure 12. Other Product Picture
Figure 13. Hospitals Pharmacy Product Picture
Figure 14. Retail Pharmacy Product Picture
Figure 15. Other Product Picture
Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers in 2022
Figure 17. Global Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Manufacturing Sites & Headquarters
Figure 18. Global Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Date of Enter into This Industry
Figure 19. Global Top 5 and 10 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players Market Share by Revenue in 2022
Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region in 2022
Figure 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region in 2022
Figure 24. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country in 2022
Figure 25. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2018-2029)
Figure 26. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2018-2029)
Figure 27. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country in 2022
Figure 30. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2018-2029)
Figure 31. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2018-2029)
Figure 32. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country in 2022
Figure 38. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2018-2029)
Figure 39. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2018-2029)
Figure 40. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. China Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country in 2022
Figure 50. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2018-2029)
Figure 51. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2018-2029)
Figure 52. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country in 2022
Figure 56. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2018-2029)
Figure 57. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2018-2029)
Figure 58. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 59. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 60. UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 61. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2018-2029)
Figure 62. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2018-2029)
Figure 63. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Type (2018-2029)
Figure 64. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2018-2029)
Figure 65. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2018-2029)
Figure 66. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Sales Channel (2018-2029)
Figure 67. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain
Figure 68. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Mode & Process
Figure 69. Direct Comparison with Distribution Share
Figure 70. Distributors Profiles
Figure 71. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Opportunities and Challenges
